AveXis Company Profile (NASDAQ:AVXS)

About AveXis (NASDAQ:AVXS)

AveXis logoAveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AVXS
  • CUSIP: N/A
  • Web: www.avexis.com
  • Market Cap: $2.32501 billion
  • Outstanding Shares: 27,794,000
Average Prices:
  • 50 Day Moving Avg: $77.42
  • 200 Day Moving Avg: $69.66
  • 52 Week Range: $31.55 - $86.76
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -20.65
  • P/E Growth: -2.03
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $7.99 per share
  • Price / Book: 10.47
  • EBIDTA: ($92,190,000.00)
  • Return on Equity: -42.28%
  • Return on Assets: -38.87%
  • Current Ratio: 8.49%
  • Quick Ratio: 8.49%
  • Average Volume: 553,024 shs.
  • Beta: 2.96
  • Short Ratio: 6.5
Frequently Asked Questions for AveXis (NASDAQ:AVXS)

What is AveXis' stock symbol?

AveXis trades on the NASDAQ under the ticker symbol "AVXS."

How were AveXis' earnings last quarter?

AveXis, Inc. (NASDAQ:AVXS) issued its quarterly earnings data on Thursday, May, 11th. The company reported ($1.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.95) by $0.13. During the same period last year, the company posted ($1.24) earnings per share. View AveXis' Earnings History.

When will AveXis make its next earnings announcement?

AveXis is scheduled to release their next quarterly earnings announcement on Wednesday, August, 9th 2017. View Earnings Estimates for AveXis.

Where is AveXis' stock going? Where will AveXis' stock price be in 2017?

8 brokerages have issued 12 month target prices for AveXis' stock. Their predictions range from $65.00 to $108.00. On average, they expect AveXis' share price to reach $93.83 in the next twelve months. View Analyst Ratings for AveXis.

What are analysts saying about AveXis stock?

Here are some recent quotes from research analysts about AveXis stock:

  • 1. According to Zacks Investment Research, "AveXis, Inc. is a gene therapy company which develops and commercializes treatments for neurological genetic diseases primarily in United States. The Company's product candidate consists of AVXS-101 which is in clinical trial for the treatment of spinal muscular atrophy Type 1, the genetic cause of infant mortality. AveXis, Inc. is headquartered in Bannockburn, Illinois. " (7/13/2017)
  • 2. Jefferies Group LLC analysts commented, "Final data from AVXS-101 in SMA T1 reported that all pts in both cohorts were event free at 13.6 mo of age compared to 25% expected via natural history, the primary EP. Motor milestones were achieved with 9 pts sitting ' 5 secs and 2 pts walking independently. We have lowered our EU T1 risk adj to 15% and began including SMA T2 into our valuation with a 75% risk adj. We reiterate our Buy rating and raise our PT to $92." (3/17/2017)
  • 3. Goldman Sachs Group, Inc. (The) analysts commented, "AVXS reported compelling gene therapy AVXS-101 Ph1 final results in spinal muscular atrophy (SMA, genetic neuromuscular disorder) Type I for all patients >13.6 months of age. The data continues to impress ' event-free survival (EFS, death or permanent ventilation) remains 100% in the 12 patients in the high dose therapeutic and notably, in the 3 non-therapeutic cohort as of 1/20. These results are remarkably better than the disease natural history of SMA Type I that suggests 25% EFS at 13.6 months. CHOP INTEND (motor function) and milestone improvements remain intact, with mean increase from baseline of +24.7 (vs. +24.8 prior) in the therapeutic dose vs. -10.5/yr per natural history. 11 (92%) patients are sitting unassisted (by definition, SMA Type I patients never sit unassisted), 9 (75%) rolling over, 2 (17%) standing alone and 2 (17%) walking independently, in line with prior 3m data. On the safety front, SAEs remain restricted to prior asymptomatic liver enzyme elevations which resolved with steroids. We look to: (1) the May 1 FDA meeting (vs. Mar) to discuss the manufacturing (CMC) outlook and June update post receipt of minutes; and (2) an end-of-Ph1 meeting with the FDA in 2Q/3Q to discuss a potential accelerated approval, which would provide upside to our estimates (we assume a 2020 launch on Ph3 data, GSe peak sales of $927mn)." (3/17/2017)
  • 4. Chardan Capital analysts commented, "On 23 December 2016, partners Biogen (NASDAQ: BIIB) and Ionis Pharmaceuticals (NASDAQ: IONS)), announced the US FDA approved Spinraza (nusinersen), a chronically-administered SMN2 antisense oligonucleotide for the treatment of spinal muscular atrophy (SMA) types 1 to 3. As discussed in our 27 December 2016 note, on efficacy, Figure 1 of the Spinraza label shows that 23% of SMA type 1 patients taking Spinraza died compared to 43% of untreated patients. We compare this to the phase I trial of AAV-based gene therapy (GT) AVXS-101 (a one-time treatment) from AveXis (Buy), where no SMA type 1 patients so far have died. On safety, as discussed in our 17 January 2017 industry note, the Spinraza label states that 11% of patients developed a platelet level below the lower limit of normal, compared to 0% of patients under sham treatment. Furthermore, as covered in both our 23 January 2017 industry note and in today's accompanying industry note, "Spinraza FDA review confirms our concerns of antisense platelet class effects", both Anthem Healthcare (unrated) and the FDA have expressed concerns regarding the safety of Spinraza."He added, "Considering the above efficacy and safety issues for Spinraza relative to AVXS-101, we reiterate our AVXS Buy rating, make AVXS a Chardan top pick for 2017, and increase our AVXS PT from $85 to $100 (+18%). We also open a pair trade of AVXS (long) and IONS (short), on the increasing potential for 1) AVXS-101 use in SMA types 2 and 3, likely at Spinraza's expense, and 2) Spinraza to increase the size of the SMA market ahead of an AVXS-101 launch." (1/26/2017)

Who are some of AveXis' key competitors?

Who are AveXis' key executives?

AveXis' management team includes the folowing people:

  • Daniel G. Welch, Independent Chairman of the Board
  • Sean Patrick Nolan, President, Chief Executive Officer, Director
  • Thomas J. Dee, Chief Financial Officer, Senior Vice President
  • Lori J. Smith, Chief Human Resource Officer, Senior Vice President
  • Michael Johannesen, Senior Vice President, Chief Compliance Officer, General Counsel
  • Andrew F. Knudten, Senior Vice President - Manufacturing and Supply Chain
  • James J. L'Italien Ph.D., Senior Vice President - Chief Regulatory and Quality Officer
  • Rick Modi, Senior Vice President, Chief Business Officer
  • Sukumar Nagendran, Senior Vice President and Chief Medical Officer
  • R. A. Session II, Senior Vice President - Corporate Strategy and Project Management

When did AveXis IPO?

(AVXS) raised $86 million in an initial public offering on Thursday, February 11th 2016. The company issued 4,300,000 shares at a price of $19.00-$21.00 per share. Goldman Sachs and Jefferies served as the underwriters for the IPO and BMO Capital Markets and Chardan were co-managers.

Who owns AveXis stock?

AveXis' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FLYNN JAMES E (8.10%) and Bank of Montreal Can (0.11%). Company insiders that own AveXis stock include Bong Y Koh, James E Flynn, Paul B Manning and Sukumar Nagendran. View Institutional Ownership Trends for AveXis.

Who bought AveXis stock? Who is buying AveXis stock?

AveXis' stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have bought AveXis stock in the last two years include Bong Y Koh and James E Flynn. View Insider Buying and Selling for AveXis.

How do I buy AveXis stock?

Shares of AveXis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AveXis' stock price today?

One share of AveXis stock can currently be purchased for approximately $83.65.

MarketBeat Community Rating for AveXis (NASDAQ AVXS)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  121 (Vote Outperform)
Underperform Votes:  59 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about AveXis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AveXis (NASDAQ:AVXS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $93.83 (12.17% upside)

Analysts' Ratings History for AveXis (NASDAQ:AVXS)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/28/2017Jefferies Group LLCReiterated RatingBuyHighView Rating Details
6/18/2017Chardan CapitalSet Price TargetBuy$103.00LowView Rating Details
6/16/2017BMO Capital MarketsReiterated RatingOutperform$95.00HighView Rating Details
6/15/2017Citigroup Inc.Set Price TargetBuy$90.00 -> $100.00LowView Rating Details
3/17/2017Goldman Sachs Group, Inc. (The)Boost Price TargetBuy$91.00 -> $108.00HighView Rating Details
11/14/2016Stifel NicolausInitiated CoverageHold$65.00N/AView Rating Details
10/21/2016Bank of America CorporationInitiated CoverageBuyN/AView Rating Details
8/17/2016Wells Fargo & CompanyUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for AveXis (NASDAQ:AVXS)
Earnings by Quarter for AveXis (NASDAQ:AVXS)
Earnings History by Quarter for AveXis (NASDAQ AVXS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017($1.06)N/AView Earnings Details
5/11/2017Q1 2017($0.95)($1.07)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.77)($0.92)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.70)($0.87)ViewListenView Earnings Details
8/11/2016Q216($0.77)($0.68)ViewListenView Earnings Details
5/12/2016Q1($0.35)($1.24)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AveXis (NASDAQ:AVXS)
Current Year EPS Consensus Estimate: $-4.42 EPS
Next Year EPS Consensus Estimate: $-4.05 EPS


Dividend History for AveXis (NASDAQ:AVXS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AveXis (NASDAQ:AVXS)
Insider Ownership Percentage: 18.60%
Institutional Ownership Percentage: 90.49%
Insider Trades by Quarter for AveXis (NASDAQ:AVXS)
Institutional Ownership by Quarter for AveXis (NASDAQ:AVXS)
Insider Trades by Quarter for AveXis (NASDAQ:AVXS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2017Sukumar NagendranVPSell1,780$81.88$145,746.40View SEC Filing  
6/1/2017Sukumar NagendranVPSell1,780$70.91$126,219.80View SEC Filing  
5/1/2017Sukumar NagendranVPSell1,780$81.39$144,874.20View SEC Filing  
4/3/2017Sukumar NagendranVPSell1,781$76.13$135,587.53View SEC Filing  
9/13/2016Paul B ManningInsiderSell289,855$34.50$9,999,997.50View SEC Filing  
2/17/2016Bong Y KohDirectorBuy100,000$20.00$2,000,000.00View SEC Filing  
2/17/2016James E FlynnInsiderBuy750,317$19.47$14,608,671.99View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AveXis (NASDAQ:AVXS)
Latest Headlines for AveXis (NASDAQ:AVXS)
americanbankingnews.com logoAveXis, Inc. (AVXS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - July 17 at 2:51 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Upgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - July 13 at 7:14 PM
americanbankingnews.com logoInsider Selling: AveXis, Inc. (AVXS) VP Sells 1,780 Shares of Stock
www.americanbankingnews.com - July 5 at 7:45 PM
americanbankingnews.com logo-$1.00 EPS Expected for AveXis, Inc. (NASDAQ:AVXS) This Quarter
www.americanbankingnews.com - July 3 at 12:48 PM
finance.yahoo.com logo4 Reasons the AveXis Inc. Rally Could Continue
finance.yahoo.com - July 1 at 4:00 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms Buy Rating for AveXis, Inc. (AVXS)
www.americanbankingnews.com - June 28 at 8:58 AM
finance.yahoo.com logoAveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - June 26 at 4:19 PM
finance.yahoo.com logoAveXis (AVXS) Jumps: Stock Rises 7.1%
finance.yahoo.com - June 22 at 11:57 AM
finance.yahoo.com logo3 Stocks You Probably Never Heard Of Could Catch Fire Soon
finance.yahoo.com - June 22 at 11:57 AM
finance.yahoo.com logoAveXis Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - June 20 at 9:28 PM
finance.yahoo.com logoBiotech Movers: AveXis, Clovis, Epizyme
finance.yahoo.com - June 20 at 4:24 PM
americanbankingnews.com logoAveXis Inc (AVXS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 20 at 12:46 PM
streetinsider.com logoAveXis (AVXS) Plans $200M Common Stock Offering
www.streetinsider.com - June 20 at 1:57 AM
reuters.com logoBRIEF-Avexis Inc says expects to submit data to FDA in August 2017 timeframe for AVXS-101
www.reuters.com - June 20 at 1:57 AM
finance.yahoo.com logoAveXis Announces Proposed Public Offering of Common Stock
finance.yahoo.com - June 19 at 8:54 PM
americanbankingnews.com logoAveXis, Inc. (AVXS) Given a $103.00 Price Target at Chardan Capital
www.americanbankingnews.com - June 19 at 2:32 PM
finance.yahoo.com logoAveXis (AVXS) Surges: Stock Moves 5% Higher
finance.yahoo.com - June 19 at 9:56 AM
americanbankingnews.com logoBMO Capital Markets Reiterates Outperform Rating for AveXis, Inc. (AVXS)
www.americanbankingnews.com - June 16 at 11:52 AM
reuters.com logoBRIEF-Avexis announces alignment with FDA on GMP commercial manufacturing process for AVXS-101
www.reuters.com - June 15 at 1:57 AM
streetinsider.com logoAveXis (AVXS) Announces Alignment with FDA on GMP for AVXS-10 Manufacturing
www.streetinsider.com - June 15 at 1:57 AM
rttnews.com logoAveXis Inc. (AVXS) Is Climbing On FDA Alignment
www.rttnews.com - June 15 at 1:57 AM
finance.yahoo.com logoAveXis Announces Alignment with FDA on GMP Commercial Manufacturing Process for AVXS-101
finance.yahoo.com - June 14 at 8:56 PM
streetinsider.com logoRegenxbio (RGNX) & AveXis (AVXS) Report New Worldwide Licenses for the Treatment of Two Rare Neurological Monogenic Disorders Using NAV AAV9 Vector
www.streetinsider.com - June 7 at 9:01 PM
americanbankingnews.com logoZacks: Analysts Expect AveXis Inc (AVXS) Will Post Earnings of -$1.02 Per Share
www.americanbankingnews.com - June 7 at 10:16 AM
americanbankingnews.com logoSukumar Nagendran Sells 1,780 Shares of AveXis Inc (AVXS) Stock
www.americanbankingnews.com - June 2 at 8:21 PM
finance.yahoo.com logoTop Gainers in the Healthcare Sector: May 22–26, 2017
finance.yahoo.com - May 31 at 3:47 PM
bizjournals.com logoNationwide Children's gets another $10M for research from Nationwide Insurance
www.bizjournals.com - May 30 at 8:52 PM
americanbankingnews.com logoAveXis Inc (AVXS) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - May 27 at 10:56 AM
americanbankingnews.com logoAveXis Inc (AVXS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 26 at 1:13 PM
americanbankingnews.com logoCitigroup Inc Reaffirms "Buy" Rating for AveXis Inc (AVXS)
www.americanbankingnews.com - May 23 at 8:07 AM
finance.yahoo.com logoWhat Falling Estimates & Price Mean for AveXis, Inc. (AVXS)
finance.yahoo.com - May 18 at 11:57 AM
americanbankingnews.com logoAveXis Inc (AVXS) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 9:24 PM
finance.yahoo.com logoAveXis reports 1Q loss
finance.yahoo.com - May 11 at 9:13 PM
finance.yahoo.com logoAveXis Reports First Quarter 2017 Financial and Operating Results
finance.yahoo.com - May 11 at 4:11 PM
americanbankingnews.com logoAveXis Inc (AVXS) Expected to Post Earnings of -$0.88 Per Share
www.americanbankingnews.com - May 11 at 2:14 PM
americanbankingnews.com logoAveXis Inc (AVXS) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - May 9 at 7:02 AM
finance.yahoo.com logoAveXis to Report First Quarter 2017 Financial and Operating Results
finance.yahoo.com - May 4 at 3:50 PM
americanbankingnews.com logoInsider Selling: AveXis Inc (AVXS) VP Sells 1,780 Shares of Stock
www.americanbankingnews.com - May 2 at 10:00 PM
americanbankingnews.com logoAveXis Inc (AVXS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 1 at 4:18 PM
finance.yahoo.com logoHigh-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids
finance.yahoo.com - April 26 at 10:59 AM
seekingalpha.com logoAveXis' Lone-Drug Bubble - Much Ado About Nothing?
seekingalpha.com - April 25 at 11:46 AM
americanbankingnews.com logoAveXis Inc (AVXS) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - April 23 at 5:02 PM
americanbankingnews.com logoZacks: Analysts Anticipate AveXis Inc (AVXS) Will Announce Earnings of -$0.88 Per Share
www.americanbankingnews.com - April 20 at 8:27 PM
americanbankingnews.com logoAveXis Inc (AVXS) Sees Large Decrease in Short Interest
www.americanbankingnews.com - April 19 at 7:47 AM
finance.yahoo.com logoAveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology
finance.yahoo.com - April 18 at 11:00 AM
americanbankingnews.com logoInsider Selling: AveXis Inc (AVXS) VP Sells 1,781 Shares of Stock
www.americanbankingnews.com - April 5 at 8:52 PM
us.rd.yahoo.com logoCoverage initiated on AveXis by UBS
us.rd.yahoo.com - March 30 at 4:09 PM
finance.yahoo.com logoAVEXIS, INC. Financials
finance.yahoo.com - March 23 at 4:10 PM
rttnews.com logoAveXis Inc. (AVXS) Surged To A New High On Positive Phase 1 Study Results
www.rttnews.com - March 20 at 9:34 AM
finance.yahoo.com logoAveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher
finance.yahoo.com - March 20 at 9:34 AM



AveXis (AVXS) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff